MedTrace Logo

"AIDA" Protocol (LAP 0493)

NCT01064557 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1068

Last updated 2020-10-14

No results posted yet for this study

Summary

The main purposes of the AIDA protocol are to test the role of intermittent maintenance therapy with ATRA, standard maintenance chemotherapy with methotrexate and 6-mercaptopurine of both in PCR negative patients at the end of the consolidation phase and to evaluate the role of allogeneic or autologous bone marrow transplantation in PCR positive patients at the end of the consolidation phase.

Conditions

Interventions

DRUG

all-trans retinoic acid (ATRA)

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-10-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Belgium
  • Germany
  • Italy
  • Netherlands
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01064557 on ClinicalTrials.gov